JANX
Janux Therapeutics Inc
16.50$
-5.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 19.9% | 21.6% | 42.5% | 5.7% | 540.8% | – | – | – | 5.0% | 113.5% | 12.6% | – | – | |
| 80.1% | 78.4% | 57.5% | 94.3% | -440.8% | – | – | – | 95.0% | -13.5% | 87.4% | 100.0% | 68.9% | |
| 472.5% | 497.4% | 1,123.8% | 167.4% | 4,240.1% | – | – | – | 346.3% | 400.4% | 718.3% | 301.9% | 388.9% | |
| 255.8% | 258.3% | 586.5% | 87.9% | 4,024.4% | – | – | – | 106.2% | 137.7% | 298.2% | 106.8% | 136.7% | |
| 708.4% | 734.1% | 1,667.8% | 249.7% | 7,723.7% | – | – | – | 447.5% | 524.6% | 1,003.9% | 408.7% | 519.2% | |
| -628.2% | -655.7% | -1,610.3% | -155.4% | -8,164.5% | – | – | – | -352.5% | -538.1% | -916.5% | -308.7% | -450.3% | |
| – | 133.1% | – | – | – | – | – | – | – | – | – | – | – | |
| -459.6% | -477.8% | -1,178.9% | -67.0% | -6,391.6% | – | – | – | -243.1% | -405.4% | -652.6% | -214.0% | -321.8% | |
| -19.9% | 38.7% | 39.0% | – | – | – | – | – | – | – | – | – | – | |
| -459.6% | -477.8% | -1,178.9% | -67.0% | -6,391.6% | – | – | – | -243.1% | -405.4% | -652.6% | -214.0% | -321.8% | |
| -439.7% | -456.2% | -1,136.4% | -61.3% | -6,275.4% | – | – | – | -238.1% | -398.8% | -640.0% | -214.0% | -317.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.